Symbols

NBIX

Neurocrine Biosciences·NASDAQ

--(--)

Signals Analysis

Bullish signal 5

Bearish signal 1

Consensus Rating "Buy"

Ample Liquidity

High Gross Profit Margin

Revenue Beats Expectation

FDA Approved

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About NBIX

Neurocrine Biosciences, Inc.

A leading neuroscience-focused biopharmaceutical company that develops pharmaceuticals for neurological, endocrine and psychiatric disorders

Industry

Pharmaceutical

Established Date

Listing Date

05/23/1996

Exchange

NASDAQ Stock Exchange

Full-time Employees

2,000

Fiscal Year Ends

12-31

Website

www.neurocrine.com

Security Type

Common stock

Office address

6027 Edgewood Bend Court, San Diego, CA 92130

Business

Introduction

Neurocrine Biosciences, Inc., was incorporated in California in January 1992 and re-incorporated in Delaware in May 1996. The company is a neuroscience-focused biopharmaceutical company dedicated to the discovery, development and commercialization of treatments for underaddressed neurological, psychiatric, endocrine and immune system diseases. Its product portfolio covers therapies approved by the U.S. Food and Drug Administration for the treatment of tardive dyskinesia, Huntington's disease-related chorea, classic congenital adrenal hyperplasia, endometriosis and uterine fibroids, and has a diversified pipeline of research in core therapeutic areas from small molecules to gene therapy.

Company Financials

EPS

NBIX has released its 2025 Q4 earnings. EPS was reported at 1.88, versus the expected 1.86, beating expectations. The chart below visualizes how NBIX has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

NBIX has released its 2025 Q4 earnings report, with revenue of 805.50M, reflecting a YoY change of 28.33%, and net profit of 153.70M, showing a YoY change of 49.08%. The Sankey diagram below clearly presents NBIX's revenue sources and cost distribution.